Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
Stephen H MandyLawrence BlondeJasvinder GillArnaud DauchyAndrius BaceviciusJodi StrongTimothy S BaileyPublished in: Diabetes, obesity & metabolism (2020)
Gla-300 tended to be associated with lower hypoglycaemia risk than SOC-BI in real-world clinical practice during the 12-month follow-up.